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New York, New York; Sydney, Australia; Basel, Switzerland; Cambridge, United Kingdom;
Boston, Massachusetts; and Toronto, Ontario, CanadaOBJECTIVES This study sought to longitudinally investigate the relationship between a broad spec-
trum of serum inﬂammatory biomarkers and plaque inﬂammation assessed by 18F-ﬂuorodeoxyglucose
positron emission tomography/computed tomography (FDG-PET/CT).
BACKGROUND Both plaque inﬂammation and serum biomarkers of inﬂammation are associated
with atherothrombotic events; however, the relationship between them is unclear.
METHODS We conducted a post hoc analysis of the dal-PLAQUE (A Randomized Placebo-Controlled
Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With
Coronary Heart Disease [CHD] Including Patients With Other CHD Risk Factors), a randomized, placebo-
controlled study of dalcetrapib, a cholesteryl ester transfer protein inhibitor, in 130 patients with coronary
heart disease, or coronary heart disease risk equivalents on stable lipid-lowering therapy. Baseline and
change after 3-month follow-up in inﬂammatory biomarker levels and baseline and change after
3-month follow-up in aorta and carotid 18F-FDG PET/CT (mean maximum target-to-background ratio
of the most diseased segment [TBRmds]) were analyzed.
RESULTS Baseline myeloperoxidase positively correlated with baseline carotid TBRmds (rho ¼ 0.25,
p ¼ 0.02). This correlation remained at the 3-month follow-up and was independent of traditional car-
diovascular disease risk factors. Baseline lipoprotein-associated phospholipase A2 mass correlated with
aorta TBRmds (rho ¼ 0.21, p ¼ 0.03). However, this correlation disappeared at the 3-month follow-up
and was not independent of cardiovascular disease risk factors. There was no association between
change from baseline in myeloperoxidase or lipoprotein-associated phospholipase A2 mass and change
from baseline in aorta and carotid TBRmds. Baseline and change from baseline in high sensitivity
C-reactive protein, interleukin 6, soluble P-selectin, soluble E-selectin, soluble intracellular adhesion
molecule 1, soluble vascular cell adhesion molecule 1, and matrix-metalloproteinase 3 and 9 did not
correlate with baseline or change from baseline in carotid or aorta TBRmds.
CONCLUSIONS Our data show that, in patients with coronary heart disease or at high risk of cor-
onary heart disease on stable lipid-lowering therapy, circulating myeloperoxidase levels are associated
with carotid plaque inﬂammation. (A Randomized, Placebo-controlled Study of the Effect of
RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Dis-
ease [CHD] Including Patients With Other CHD Risk Factors [dal-PLAQUE]; NCT00655473) (J Am Coll
Cardiol Img 2013;6:1087–94) ª 2013 by the American College of Cardiology Foundation
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1088nﬂammation is increasingly being recognized as a In the current study, we therefore longitudinally
pivotal feature of atherosclerosis and a potential
target for therapy (1). Pathology studies have
shown that the immediate site of plaque rupture
contains a high concentration of inﬂammatory cells
(2). In subjects who die of acute myocardial in-
farction, plaques throughout the coronary arteries are
diffusely inﬁltrated by inﬂammatory cells, in contrast
to patients who die of other causes, suggesting a
generally inﬂamed state of the vasculature in patients
with acute coronary syndromes (3). Also, various
serum inﬂammatory biomarkers have been identiﬁed
as independent predictors of future atherothrombotic
events (4–13). Thus, both plaque inﬂammation and
serum biomarkers of inﬂammation are associated
with atherothrombotic events; however, little isFrom the *T
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Recent advances in the development of
noninvasive imaging techniques have
enabled quantiﬁcation of vessel wall in-
ﬂammation with 18F-ﬂuorodeoxyglucose
positron emission tomography/computed
tomography (18F-FDG PET/CT). In-
ﬂammatory cells have high metabolic ac-
tivity, especially when they are activated,
which markedly enhances their 18F-FDG
uptake against background tissues (14).
Studies in experimental atherosclerotic
rabbit models, as well as human endarter-
ectomy studies, have shown that 18F-FDG
accumulation in plaque correlates with
plaque macrophage content (15,16). Some
studies have previously investigated the
relationship between serum biomarkers of
inﬂammation and vessel wall 18F-FDG
PET/CT; however, these studies either
included a small number of patients orlacked longitudinal follow-up, and their results are
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Controlled Study of the Effect of RO4607381
on Progression or Regression of Atherosclerotic
Plaque in Patients With Coronary Heart Disease
[CHD] Including Patients With Other CHD Risk
Factors) study (22).
METHODS
The design and study methods of the dal-
PLAQUE study have been described previously
(22). In summary, dal-PLAQUE was a phase-2b
double-blind, randomized, placebo-controlled,
multicenter study to investigate the effect of dalce-
trapib, a cholesteryl ester transfer protein inhibitor,
on vessel wall inﬂammation assessed by 18F-FDG
PET/CT. Participants were adults with either pre-
vious known coronary heart disease or at high risk of
coronary heart disease with triglyceride concentra-
tions #400 mg/dl, low-density lipoprotein choles-
terol concentrations <100 mg/dl (or on maximum
tolerated doses of statins), and carotid or aortic
arterial wall (target) to background (blood) ratio
(TBR) of 1.6 or higher. Details of 18F-FDG PET/
CT imaging procedures and analyses have been
published previously (22). For the current analyses,
we used baseline values and change after 3 months
of follow-up of mean maximum TBR of the most
diseased segment (TBRmds).
We examined inﬂammatory biomarker data for
baseline and change from baseline after 3-month
follow-up. Inﬂammatory biomarker assays were per-
formed byMedpace Reference Laboratories (Medpace
Inc., Cincinnati, Ohio). Serum high-sensitivity C-
reactive protein (hsCRP) levels were assessed by
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1089Behring, Deerﬁeld, Illinois). Serum levels of
interleukin (IL)-6, soluble P-selectin (sP-selectin), and
soluble E-selectin (sE-selectin) were determined using
Millipore immunodetection kits and the Luminex
system (Millipore, Billerica, Massachusetts). Plasma
levels of soluble intracellular adhesion molecule
(sICAM)-1 and soluble vascular cell adhesionmolecule
(sVCAM)-1, and serum levels of matrix metal-
loproteinase (MMP)-3 and -9 were determined using
analyte-speciﬁc sandwich enzyme-linked immuno-
sorbent assay kits from R&D systems (Minneapolis,
Minnesota) and a Tecan Sunrise microplate reader
(Tecan Group Ltd., Männedorf, Switzerland). Mye-
loperoxidase (MPO) levels in heparin plasma were
determined using the Prognostix CardioMPO
enzyme-linked immunosorbent assay kit (Cleveland
Heart Lab, Cleveland, Ohio). Lipoprotein-associated
phospholipase A2 (Lp-PLA2) mass was assessed us-
ing enzyme-linked immunosorbent assay with PLAC
Test reagents (diaDexus, San Francisco, California) at
Berkeley HeartLab (Alameda, California).
Statistical methods. All continuous variables are
expressed as mean  SD and categorical data are
expressed as absolute numbers and percentages.
Pearson correlation coefﬁcients and Student t tests
were used to assess the association between
aorta and carotid TBRmds and traditional cardio-
vascular disease risk factors (age, male sex, body
mass index, current smoking, hypertension, diabetes
mellitus, history of coronary heart disease, total
cholesterol, low-density lipoprotein cholesterol,
high-density lipoprotein cholesterol, and tri-
glycerides). Spearman rhos were used to assess the
association between baseline and change from
baseline in serum inﬂammatory biomarkers and
baseline and change from baseline in TBRmds.
Student t tests were used to compare TBRmds in
the highest and lowest quartiles of MPO and Lp-
PLA2 mass. Multivariate linear regression analyses
were used to compare TBRmds in the highest and
lowest quartiles of MPO and Lp-PLA2 mass,
adjusting for traditional cardiovascular disease risk
factors. TBRmds was the response variable, and the
highest and lowest quartiles of MPO and Lp-PLA2
mass and traditional cardiovascular disease risk
factors were the explanatory variables. All statistical
analyses were performed using IBM SPSS statistical
package (version 19.0, Armonk, New York).
RESULTS
This study included 130 patients. Patient charac-
teristics have been previously published (22).
Eligible serum inﬂammatory biomarker data atbaseline and 3-month follow-up were obtained in
128 and 125 patients, respectively. Eligible aorta
18F-FDG PET/CT data at baseline and 3-month
follow-up were obtained in 105 and 104 patients,
respectively. Eligible carotid 18F-FDG PET/CT
data at baseline and 3-month follow-up were ob-
tained in 87 and 50 patients, respectively.
Concerning the relationship between 18F-FDG
PET/CT and traditional cardiovascular risk factors,
baseline aorta TBRmds correlated with baseline low-
density lipoprotein cholesterol (r ¼ 0.29, p ¼ 0.04),
and a higher baseline carotid TBRmds was found in
male subjects (1.75  0.23 vs. 2.08  0.44,
p ¼ 0.004). Higher increase from baseline aorta
TBRmds was found in hypertensive subjects and
nonsmokers (–0.46  0.40 vs. –0.12  0.41,
p ¼ 0.02; and –0.15  0.42 vs. –0.51  0.31,
p ¼ 0.05, respectively), and higher increase from
baseline in carotid TBRmds was associated with
higher age (r ¼ 0.49, p ¼ 0.01).
Serum inﬂammatory biomarkers and 18F-FDG PET/CT
imaging. At baseline, MPO levels were associated
with carotid TBRmds (Table 1). When baseline
MPO levels were divided into quartiles, subjects in
the highest MPO quartile had signiﬁcantly higher
carotid TBRmds values than did those in the lowest
MPO quartile (Fig. 1). This relation remained
present at 3-month follow-up and was independent
of cardiovascular disease risk factors. There was no
association between change from baseline in MPO
and change from baseline in aorta and carotid
TBRmds.
At baseline, Lp-PLA2 mass levels were associated
with aorta TBRmds (Table 1). However, when
baseline Lp-PLA2 mass levels were divided into
quartiles, there was no signiﬁcant difference be-
tween subjects in the highest quartile versus in the
lowest Lp-PLA2 mass quartile (Fig. 2).
The other baseline serum biomarkers of inﬂam-
mation were not associated with baseline or change
from baseline in aorta and carotid TBRmds (Tables 1
and 2). Similarly, changes from baseline in serum
biomarkers of inﬂammation were not associated
with changes from baseline in aorta and carotid
TBRmds (Table 3).
The only observed differences in change from
baseline in serum inﬂammatory biomarkers between
the dalcetrapib and placebo group (data not shown)
were an increase in IL-6 (2.15  7.83 vs. –0.28 
3.41, p ¼ 0.03) and Lp-PLA2 mass (10.7  40.2 vs.
–2.79  27.5, p ¼ 0.03), and a decrease in sP-
selectin (0.55  12.8 vs. 5.14  12.0, p ¼ 0.04)
in the dalcetrapib versus placebo group after
3-month follow-up.
Table 1. Spearman Rhos to Assess the Correlation Between Baseline
Inﬂammatory Biomarkers and Baseline Aorta and Carotid TBRmds
Assessed by 18F-FDG PET/CT
Aorta TBRmds Carotid TBRmds
Rho p Value Rho p Value
High-sensitivity C-reactive protein 0.07 0.51 0.05 0.64
Lipoprotein-associated phospholipase
A2 mass
0.21 0.03* 0.11 0.32
Interleukin-6 0.05 0.60 0.03 0.77
Soluble P-selectin 0.17 0.09 0.14 0.20
Soluble E-selectin 0.13 0.18 0.10 0.36
Soluble intracellular adhesion molecule-1 0.02 0.81 0.18 0.11
Soluble vascular cell adhesion molecule-1 0.03 0.80 0.15 0.18
Matrix metalloproteinase-3 0.02 0.85 0.03 0.76
Matrix metalloproteinase-9 0.16 0.10 0.20 0.06
Myeloperoxidase 0.19 0.06 0.25 0.02*
*Signiﬁcant correlations.
18F-FDG PET/CT ¼ ﬂuorodeoxyglucose F 18 positron emission tomography/computed
tomography; TBRmds ¼ mean maximum most diseased segment target-to-background ratio.
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1090DISCUSS ION
The aim of the present post hoc analysis in the dal-
PLAQUE study was to determine the relationship
between serum inﬂammatory biomarkers and local
vessel wall inﬂammation quantiﬁed by 18F-FDG
PET/CT. We observed a positive correlation be-
tween baseline serum MPO and baseline carotidRmds Values at Baseline and 3-Month Follow-Up for
les
peroxidase (MPO) values were associated with higher baseline ca-
ound ratio of the most diseased segment (TBRmds) values, and this
sent at 3-month follow-up. The p values are for the comparison be-
highest quartiles (Q). Adj P ¼ p values adjusted for age, sex, body
ity lipoprotein cholesterol, high-density lipoprotein cholesterol, hy-
ellitus, history of coronary heart disease, and current smoking.TBRmds. This relation remained present at 3-month
follow-up and was independent of traditional risk
factors. Baseline Lp-PLA2 mass positively corre-
lated with baseline aorta TBRmds. However, this
relationship disappeared after 3 months of follow-
up and was not independent of traditional risk
factors.
Traditional risk factors for cardiovascular disease and
vessel wall inﬂammation. Previous cross-sectional
studies have investigated the relationship between
traditional risk factors and vessel wall inﬂammation.
In patients who underwent 18F-FDG PET/CT
imaging for cancer screening, carotid 18F-FDG
uptake was associated with waist circumference,
hypertension, glucose intolerance, and metabolic
syndrome (23). In patients with known coronary
artery disease or multiple cardiovascular risk factors,
carotid 18F-FDG uptake was higher in patients with
known coronary artery disease and in men (17). In
another study including coronary artery disease pa-
tients, carotid 18F-FDG uptake was associated with
obesity, increasing age, hypertension, smoking,
and male sex (24). A recent study found higher
carotid 18F-FDG uptake in diabetic patients than in
nondiabetic patients (25).
The current studydthe ﬁrst to assess the rela-
tionship between cardiovascular disease risk factors
and change in vessel wall 18F-FDG uptake longi-
tudinallydcorroborates these ﬁndings in that we
found age and hypertension to be important pre-
dictors for increase in vessel wall inﬂammation.
Baseline aorta TBRmds positively correlated with
baseline low-density lipoprotein cholesterol, and
baseline carotid TBRmds was higher in male sub-
jects. Change from baseline in aorta TBRmds was
higher in hypertensive subjects and surprisingly also
in nonsmokers. Change from baseline in carotid
TBRmds positively correlated with age. However, we
did not ﬁnd a relationship among body mass index,
diabetes, and vessel wall inﬂammation, which were
found to be so markedly related in previous studies.
One explanation is the selected population. One
inclusion criterion was triglyceride concentrations
#400 mg/dl. Serum triglyceride levels are strongly
associated with body mass index and diabetes,
and therefore this might have obscured the rela-
tionship between body mass index and diabetes with
vessel wall inﬂammation. Furthermore, all subjects
were on statin therapy with either low-density li-
poprotein cholesterol <100 mg/dl or on maximum
tolerated doses of statins, which might also have
inﬂuenced the relationship between traditional car-
diovascular disease risk factors and vessel wall
inﬂammation.
Figure 2. Aortic TBRmds Values at Baseline and 3-Month Follow-Up for
Baseline Lp-PLA2 Mass Quartiles
Although there is a trend toward higher baseline aorta TBRmds in higher baseline
lipoprotein-associated phospholipase A2 (Lp-PLA2) mass quartiles, this relation is not in-
dependent of other risk factors and the relation disappears after 3-month follow-up. The p
values are for the comparison between the lowest and highest quartiles. Abbreviations as in
Figure 1.
Table 2. Spearman Rhos to Assess the Correlation Between Baseline Inﬂammatory
Biomarkers and Change From Baseline in Aorta and Carotid TBRmds Assessed by
18F-
FDG PET/CT
Aorta TBRmds Carotid TBRmds
Rho p Value Rho p Value
High-sensitivity C-reactive protein 0.11 0.25 0.02 0.91
Lipoprotein-associated phospholipase
A2 mass
0.16 0.10 0.07 0.62
Interleukin-6 0.16 0.11 0.07 0.63
Soluble P-selectin 0.17 0.09 0.16 0.28
Soluble E-selectin 0.00 0.98 0.05 0.75
Soluble intracellular adhesion molecule-1 0.14 0.16 0.14 0.32
Soluble vascular cell adhesion molecule-1 0.02 0.84 0.19 0.20
Matrix metalloproteinase-3 0.01 0.96 0.16 0.26
Matrix metalloproteinase-9 0.15 0.14 0.14 0.35
Myeloperoxidase 0.04 0.69 0.09 0.55
Abbreviations as in Table 1.
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1091Inﬂammatory biomarkers and vessel wall inﬂammation.
Various studies have investigated the relationship
between serum biomarkers of inﬂammation and
vessel wall 18F-FDG uptake. However, ours is the
ﬁrst study to investigate a broad panel of inﬂam-
matory biomarkers and their relationship with vessel
wall inﬂammation quantiﬁed by 18F-FDG PET/
CT in a longitudinal study.
CRP AND IL-6. Both increased CRP and IL-6 are
associated with increased cardiovascular disease risk
(4,5). Previous studies have shown contradicting
results regarding the relationship between vessel
wall 18F-FDG uptake and CRP and IL-6. Yoo
et al. (19) observed in 120 healthy individuals that
mean and maximum carotid TBR correlated with
hsCRP. Yang et al. (20) performed 18F-FDG PET/
CT in 142 nondiabetic subjects without history of
cardiovascular disease and showed that carotid mean
TBR was higher in subjects with a higher hsCRP
($2.0 mg/dl) than in subjects with a lower hsCRP
(<2.0 mg/dl). On the other hand, a study by Rudd
et al. (17) in 33 patients with known coronary artery
disease or multiple cardiovascular risk factors found
no correlation between carotid and aorta 18F-FDG
uptake and serum CRP, IL-6, and other markers of
systemic inﬂammation, namely IL-10, IL-18, and
tumor necrosis factor-alpha (17). Similarly, Wu
et al. (18) did not observe a relationship between
hsCRP levels and 18F-FDG PET/CT in patients
with carotid stenosis $70%. In another study by
Wu et al. (21), in 43 statin-naive subjects with
clinical evidence of atherosclerosis, mean TBR of
various segments of the aorta, and iliofemoral ar-
teries did not correlate with hsCRP. Interestingly,
the 2 studies in which CRP correlated with 18F-
FDG PET/CT were both performed in healthy
individuals. In contrast, the 4 studies (including our
current report) that did not show a relationship
among vessel wall inﬂammation, CRP and IL-6
were all conducted in subjects with atherosclerotic
disease.
LP-PLA2. Increased serum levels of Lp-PLA2 mass
and activity are associated with increased risk of
cardiovascular events (8,9). One previous study has
investigated the relationship between Lp-PLA2 and
vessel wall 18F-FDG uptake and observed that, in
120 healthy individuals, mean and maximum ca-
rotid TBR did not correlate with Lp-PLA2 (19). In
the current study, we found a correlation between
baseline Lp-PLA2 and baseline aorta TBRmds.
However, when Lp-PLA2 mass levels were divided
into quartiles, there was no signiﬁcant difference in
aorta TBRmds between the highest versus the lowestLp-PLA2 mass quartile at baseline and 3-month
follow-up.
SP-SELECTIN, SE-SELECTIN, SICAM-1, AND SVCAM-1. In-
creased serum levels of P-selectin, E-selectin,
ICAM-1, and VCAM-1 are predictive of coronary
heart disease (10,11). One study performed
by Wu et al. (21) investigated the relationship
among ICAM-1, VCAM-1, and E-selectin, and
mean TBR of various segments of the aorta and
iliofemoral arteries in statin-naive subjects with
Table 3. Spearman Rhos to Assess the Correlation Between Change From
Baseline Inﬂammatory Biomarkers and Change From Baseline in Aorta and
Carotid TBRmds Assessed by
18F-FDG PET/CT
Aorta
TBRmds
Carotid
TBRmds
Rho p Value Rho p Value
High-sensitivity C-reactive protein 0.09 0.56 0.02 0.95
Lipoprotein-associated phospholipase A2 mass 0.27 0.06 0.28 0.19
Interleukin-6 0.08 0.59 0.12 0.59
Soluble P-selectin 0.03 0.83 0.11 0.61
Soluble E-selectin 0.03 0.86 0.10 0.64
Soluble intracellular adhesion molecule-1 0.03 0.85 0.21 0.33
Soluble vascular cell adhesion molecule-1 0.03 0.83 0.24 0.27
Matrix-metalloproteinase-3 0.17 0.25 0.05 0.83
Matrix-metalloproteinase-9 0.02 0.89 0.02 0.92
Myeloperoxidase 0.21 0.16 0.33 0.11
Abbreviations as in Table 1.
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1092clinical evidence of atherosclerosis. Similar to the
results of our analyses, they did not ﬁnd a correla-
tion between these biomarkers and vessel wall
inﬂammation.
MMP-3 AND MMP-9. Epidemiological studies have
shown that increased serum MMP-3 and MMP-9
levels are associated with increased future risk of
atherothrombotic events (12,13). Two studies have
investigated the relationship among MMP-3,
MMP-9, and vessel wall 18F-FDG uptake. The
ﬁrst study was performed by Rudd et al. (17) in
patients with known coronary artery disease or
multiple cardiovascular risk factors. They showed a
positive correlation among MMP-3 and MMP-9
levels and vessel wall 18F-FDG uptake. The sec-
ond study was performed by Wu et al. (21) in
statin-naive subjects with clinical evidence of
atherosclerosis. All subjects were treated with
atorvastatin for 12 weeks. At baseline, mean TBR
of various segments of the aorta and iliofemoral
arteries correlated with MMP-9. The correlation
between 18F-FDG uptake and MMP-9 was not
independent of other risk factors. The decline in
mean TBR after statin treatment correlated with
the MMP-9 reduction. Our study does not
corroborate with both previous studies, because we
did not ﬁnd a relationship amongMMP-3,MMP-
9, and vessel wall 18F-FDG uptake.
MPO. MPO is a peroxidase identiﬁed in athero-
sclerotic plaques (26) with pro-atherogenic effects
that comprise oxidation of LDL (27) and oxidative
modiﬁcation of apolipoprotein A-I, altering itscapacity to promote cholesterol efﬂux (28). Its ef-
fects on nitric oxide bioavailability and induction
of hypochlorous acids result in endothelial dys-
function (29) and can promote endothelial cell
apoptosis and detachment, making plaques prone to
rupture (30).
Our study is the ﬁrst to investigate the relationship
between MPO and vessel wall 18F-FDG uptake.
We observed a marked correlation between MPO
and carotid TBRmds at baseline. This correlation
remained present at 3-month follow-up. Baseline
and change in MPO levels were not associated with
change in carotid TBRmds. Apparently, subjects with
higher MPO levels have a constantly higher degree
of vessel wall inﬂammation.
Daugherty et al. (26) investigated the presence of
MPO in atherosclerotic lesions. Interestingly, they
observed striking colocalization of immunostaining
for MPO and macrophages in atherosclerotic
plaques. In fact, both were especially prominent in
shoulder regions of the plaques. Thus, vessel wall
18F-FDG uptake correlates with plaque macrophage
content (15,16), and plaque macrophage content
correlates with plaque MPO content (26). This
makes it biologically plausible that MPO levels
can show a relationship with vessel wall 18F-FDG
uptake.
Study limitations. First, we pooled the data of
serum biomarkers of inﬂammation and 18F-FDG
PET/CT of both the dalcetrapib- and placebo-
treated patients. However, we did not observe
an effect of dalcetrapib on TBRmds or serum bio-
markers of inﬂammation, except for IL-6,
Lp-PLA2, and sP-selectin. Second, MPO was
measured in plasma. MPO levels may be related to
leukocytes. Leukocytes are a known, strong pre-
dictor of cardiovascular disease. Unfortunately, we
could not assess cellular MPO, as there are no
samples left from the study. Of note, most publi-
cations refer to serum MPO levels when predicting
cardiovascular disease risk. Third, we investigated
a selected population with a high risk of coronary
heart disease, all on statin therapy with low-density
lipoprotein cholesterol concentrations <100 mg/dl
or on maximum tolerated doses of statins. The
fact that we investigated a small and limited patient
collective (no patients without disease were in-
cluded) might have obscured the relationship be-
tween vessel wall inﬂammation and circulating
markers of inﬂammation. Fourth, although this
is an exploratory post hoc analysis, we did not
account for multiple testing, which makes our
analysis prone to type 1 error. Furthermore, many
inﬂammatory markers correlate with each other,
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Finally, it is unknown if vessel wall inﬂammation
measured by 18F-FDG PET/CT is predictive
for future cardiovascular events. Longitudinal stu-
dies are currently ongoing to investigate such a
relation (31).
CONCLUS IONS
Of the broad panel of inﬂammatory biomar-
kers evaluated in this longitudinal study, we ob-
served a positive correlation between baseline serum
MPO and baseline carotid TBRmds. This relation
remained present at 3-month follow-up and wasindependent of traditional cardiovascular disease
risk factors. The other inﬂammatory biomarkers
did not correlate with aorta and carotid TBRmds.
Our data show that, in patients with coronary
heart disease or at high risk of coronary heart
disease on stable lipid-lowering therapy, circulating
MPO levels are associated with carotid plaque
inﬂammation.
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